Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas

Mika Hilvo, Ines De Santiago, Peddinti Gopalacharyulu, Wolfgand D. Schmitt, Jan Budczies, Marc Kuhberg, Manfred Dietel, Tero Aittokallio, Florian Markowetz, Carsten Denkert, Jalid Sehouli, Christian Frezza, Silvia Darb-Esfahani, Elena Ioana Braicu

Research output: Contribution to journalArticleScientificpeer-review

18 Citations (Scopus)

Abstract

Ovarian cancer is a heterogeneous disease of low prevalence, but poor survival. Early diagnosis is critical for survival, but it is often challenging because the symptoms of ovarian cancer are subtle and become apparent only during advanced stages of the disease. Therefore, the identification of robust biomarkers of early disease is a clinical priority. Metabolomic profiling is an emerging diagnostic tool enabling the detection of biomarkers reflecting alterations in tumor metabolism, a hallmark of cancer. In this study, we performed metabolomic profiling of serum and tumor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients with benign or non-neoplastic lesions. We report metabolites of hydroxybutyric acid (HBA) as novel diagnostic and prognostic biomarkers associated with tumor burden and patient survival. The accumulation of HBA metabolites caused by HGSOC was also associated with reduced expression of succinic semialdehyde dehydrogenase (encoded by ALDH5A1), and with the presence of an epithelial-to-mesenchymal transition gene signature, implying a role for these metabolic alterations in cancer cell migration and invasion. In conclusion, our findings represent the first comprehensive metabolomics analysis in HGSOC and propose a new set of metabolites as biomarkers of disease with diagnostic and prognostic capabilities.
Original languageEnglish
Pages (from-to)796-804
JournalCancer Research
Volume76
Issue number4
DOIs
Publication statusPublished - 2016
MoE publication typeA1 Journal article-refereed

Fingerprint

Hydroxybutyrates
Ovarian Neoplasms
Biomarkers
Metabolomics
Carcinoma
Survival
Neoplasms
Succinate-Semialdehyde Dehydrogenase
Epithelial-Mesenchymal Transition
Tumor Burden
Cell Movement
Early Diagnosis
Serum
Genes

Cite this

Hilvo, M., De Santiago, I., Gopalacharyulu, P., Schmitt, W. D., Budczies, J., Kuhberg, M., ... Braicu, E. I. (2016). Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas. Cancer Research, 76(4), 796-804. https://doi.org/10.1158/0008-5472.CAN-15-2298
Hilvo, Mika ; De Santiago, Ines ; Gopalacharyulu, Peddinti ; Schmitt, Wolfgand D. ; Budczies, Jan ; Kuhberg, Marc ; Dietel, Manfred ; Aittokallio, Tero ; Markowetz, Florian ; Denkert, Carsten ; Sehouli, Jalid ; Frezza, Christian ; Darb-Esfahani, Silvia ; Braicu, Elena Ioana. / Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas. In: Cancer Research. 2016 ; Vol. 76, No. 4. pp. 796-804.
@article{ccb85897be02402e9db8841034389b0f,
title = "Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas",
abstract = "Ovarian cancer is a heterogeneous disease of low prevalence, but poor survival. Early diagnosis is critical for survival, but it is often challenging because the symptoms of ovarian cancer are subtle and become apparent only during advanced stages of the disease. Therefore, the identification of robust biomarkers of early disease is a clinical priority. Metabolomic profiling is an emerging diagnostic tool enabling the detection of biomarkers reflecting alterations in tumor metabolism, a hallmark of cancer. In this study, we performed metabolomic profiling of serum and tumor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients with benign or non-neoplastic lesions. We report metabolites of hydroxybutyric acid (HBA) as novel diagnostic and prognostic biomarkers associated with tumor burden and patient survival. The accumulation of HBA metabolites caused by HGSOC was also associated with reduced expression of succinic semialdehyde dehydrogenase (encoded by ALDH5A1), and with the presence of an epithelial-to-mesenchymal transition gene signature, implying a role for these metabolic alterations in cancer cell migration and invasion. In conclusion, our findings represent the first comprehensive metabolomics analysis in HGSOC and propose a new set of metabolites as biomarkers of disease with diagnostic and prognostic capabilities.",
author = "Mika Hilvo and {De Santiago}, Ines and Peddinti Gopalacharyulu and Schmitt, {Wolfgand D.} and Jan Budczies and Marc Kuhberg and Manfred Dietel and Tero Aittokallio and Florian Markowetz and Carsten Denkert and Jalid Sehouli and Christian Frezza and Silvia Darb-Esfahani and Braicu, {Elena Ioana}",
year = "2016",
doi = "10.1158/0008-5472.CAN-15-2298",
language = "English",
volume = "76",
pages = "796--804",
journal = "Cancer Research",
issn = "0008-5472",
number = "4",

}

Hilvo, M, De Santiago, I, Gopalacharyulu, P, Schmitt, WD, Budczies, J, Kuhberg, M, Dietel, M, Aittokallio, T, Markowetz, F, Denkert, C, Sehouli, J, Frezza, C, Darb-Esfahani, S & Braicu, EI 2016, 'Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas', Cancer Research, vol. 76, no. 4, pp. 796-804. https://doi.org/10.1158/0008-5472.CAN-15-2298

Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas. / Hilvo, Mika; De Santiago, Ines; Gopalacharyulu, Peddinti; Schmitt, Wolfgand D.; Budczies, Jan; Kuhberg, Marc; Dietel, Manfred; Aittokallio, Tero; Markowetz, Florian; Denkert, Carsten; Sehouli, Jalid; Frezza, Christian; Darb-Esfahani, Silvia; Braicu, Elena Ioana.

In: Cancer Research, Vol. 76, No. 4, 2016, p. 796-804.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas

AU - Hilvo, Mika

AU - De Santiago, Ines

AU - Gopalacharyulu, Peddinti

AU - Schmitt, Wolfgand D.

AU - Budczies, Jan

AU - Kuhberg, Marc

AU - Dietel, Manfred

AU - Aittokallio, Tero

AU - Markowetz, Florian

AU - Denkert, Carsten

AU - Sehouli, Jalid

AU - Frezza, Christian

AU - Darb-Esfahani, Silvia

AU - Braicu, Elena Ioana

PY - 2016

Y1 - 2016

N2 - Ovarian cancer is a heterogeneous disease of low prevalence, but poor survival. Early diagnosis is critical for survival, but it is often challenging because the symptoms of ovarian cancer are subtle and become apparent only during advanced stages of the disease. Therefore, the identification of robust biomarkers of early disease is a clinical priority. Metabolomic profiling is an emerging diagnostic tool enabling the detection of biomarkers reflecting alterations in tumor metabolism, a hallmark of cancer. In this study, we performed metabolomic profiling of serum and tumor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients with benign or non-neoplastic lesions. We report metabolites of hydroxybutyric acid (HBA) as novel diagnostic and prognostic biomarkers associated with tumor burden and patient survival. The accumulation of HBA metabolites caused by HGSOC was also associated with reduced expression of succinic semialdehyde dehydrogenase (encoded by ALDH5A1), and with the presence of an epithelial-to-mesenchymal transition gene signature, implying a role for these metabolic alterations in cancer cell migration and invasion. In conclusion, our findings represent the first comprehensive metabolomics analysis in HGSOC and propose a new set of metabolites as biomarkers of disease with diagnostic and prognostic capabilities.

AB - Ovarian cancer is a heterogeneous disease of low prevalence, but poor survival. Early diagnosis is critical for survival, but it is often challenging because the symptoms of ovarian cancer are subtle and become apparent only during advanced stages of the disease. Therefore, the identification of robust biomarkers of early disease is a clinical priority. Metabolomic profiling is an emerging diagnostic tool enabling the detection of biomarkers reflecting alterations in tumor metabolism, a hallmark of cancer. In this study, we performed metabolomic profiling of serum and tumor tissue from 158 patients with high-grade serous ovarian cancer (HGSOC) and 100 control patients with benign or non-neoplastic lesions. We report metabolites of hydroxybutyric acid (HBA) as novel diagnostic and prognostic biomarkers associated with tumor burden and patient survival. The accumulation of HBA metabolites caused by HGSOC was also associated with reduced expression of succinic semialdehyde dehydrogenase (encoded by ALDH5A1), and with the presence of an epithelial-to-mesenchymal transition gene signature, implying a role for these metabolic alterations in cancer cell migration and invasion. In conclusion, our findings represent the first comprehensive metabolomics analysis in HGSOC and propose a new set of metabolites as biomarkers of disease with diagnostic and prognostic capabilities.

U2 - 10.1158/0008-5472.CAN-15-2298

DO - 10.1158/0008-5472.CAN-15-2298

M3 - Article

VL - 76

SP - 796

EP - 804

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 4

ER -